Journal of Postgraduate Medicine, Education and Research

Register      Login

VOLUME 46 , ISSUE 2 ( April-June, 2012 ) > List of Articles

MEETING REPORT

Mesenchymal Stem Cells: The New Immunosuppressants?

Varun Dhir

Citation Information : Dhir V. Mesenchymal Stem Cells: The New Immunosuppressants?. J Postgrad Med Edu Res 2012; 46 (2):63-68.

DOI: 10.5005/jp-journals-10028-1015

Published Online: 01-03-2014

Copyright Statement:  Copyright © 2012; The Author(s).


Abstract

Key messages

(1) Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate only in one lineage (mesodermal). (2) They were first discovered in the bone marrow and this remains a common source, followed by adipose tissue. There are other sources: Synovial fluid, umbilical cord blood, amniotic fluid, placenta, fetal liver. (3) MSCs are immunosuppressive, the mechanism of which is not fully elucidated, but involves action on other cells mainly through soluble mediators, like TGFβ, IDO, IL-1, NO, etc. (4) MSCs have shown efficacy in various animal models of autoimmune diseases. There have been small human studies, some of which showed benefit, however, a single randomized controlled trial has been done. (5) MSCs may have a role in autoimmune diseases refractory to treatment or as an add onto prevent treatment side effects.

How to cite this article

Dhir V. Mesenchymal Stem Cells: The New Immunosuppressants? J Postgrad Med Edu Res 2012;46(2):63-68.


PDF Share
  1. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy Position Statement. Cytotherapy 2005;7(5):393-95.
  2. Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation. J Cell Biochem 1997 Feb;64(2):278-94.
  3. Characterization of cells with osteogenic potential from human marrow. Bone 1992;13(1):81-88.
  4. Multilineage potential of adult human mesenchymal stem cells. Science 1999 Apr 2;284(5411):143-47.
  5. Effect of transplantation of bone marrow cells on morphology of rat myocardium after cryodestruction. Bull Exp Biol Med 2009 Apr;147(4):517-20.
  6. Precursors for fibroblasts in different population of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol 1974;2(2):83-92.
  7. Osteogenesis in transplants of bone marrow cells. J Embryol Exp Morphol 1966 Dec;16(3):381-90.
  8. Mesenchymal stem cells. J Orthop Res 1991 Sep;9(5):641-50.
  9. Immunomodulatory properties of human adult and fetal multipotent mesenchymal stem cells. J Biomed Sci 2011;18:49
  10. Multilineage cells from human adipose tissue: Implications for cell-based therapies. Tissue Eng 2001 Apr;7(2):211-28.
  11. The origins of mesenchymal stromal cell heterogeneity. Stem Cell Rev 2011 Sep;7(3):560-68.
  12. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002 Jan;30(1):42-48.
  13. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006;8(4):315-17.
  14. Concise review: Mesenchymal stem cells: Their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 2007 Nov;25(11):2739-49.
  15. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003 Oct;31(10):890-96.
  16. Characterization and functionality of cell surface molecules on human mesenchymal stem cells. J Biomed Sci 2003 Mar-Apr;10(2):228-41.
  17. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003 May 1;101(9):3722-29.
  18. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J Immunol 2010 July 1;185(1):302-12.
  19. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005 Apr 1;105(7):2821-27.
  20. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005 Feb 15;105(4):1815-22.
  21. Human mesenchymal stem cells modulate B-cell functions. Blood 2006 Jan 1;107(1):367-72.
  22. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005 May 15;105(10):4120-26.
  23. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: Central role of MSC-derived prostaglandin E2. Blood 2009 June 25;113(26):6576-83.
  24. Mesenchymal stem cell-natural killer cell interactions: Evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 2006 Feb 15;107(4):1484-90.
  25. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006 Jan;24(1):74-85.
  26. Mesenchymal stem cells and autoimmune diseases. Best Pract Res Clin Haematol 2011 Mar;24(1):49-57.
  27. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006 Feb;24(2):386-98.
  28. A new mesenchymal stem cell (MSC) paradigm: Polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype. PloS one 2010;5(4):e10088
  29. A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. Blood 2007 Nov 15;110(10):3691-94.
  30. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clin Exp Immunol 2009 Apr;156(1):149-60.
  31. Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp Hematol 2005 Aug;33(8):928-34.
  32. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004 June 15;103(12):4619-21.
  33. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007 Jan 1;109(1):228-34.
  34. The negative co-signaling molecule b7-h4 is expressed by human bone marrow-derived mesenchymal stem cells and mediates its T-cell modulatory activity Stem Cells Dev 2010 Jan;19(1):27-38.
  35. Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica 2007 Jul;92(7):881-88.
  36. Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted T-cell responses against viral or tumor-associated antigens. Stem Cells 2008 May;26(5):1275-87.
  37. Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis. Arch Neurol 2008 Jun;65(6):753-61.
  38. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum 2007 Apr;56(4):1175-86.
  39. Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheum 2009 Apr;60(4):1006-19.
  40. Flk-1+ mesenchymal stem cells aggravate collagen-induced arthritis by up-regulating interleukin-6. Clin Exp Immunol 2010 Mar;159(3):292-302.
  41. Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis. Arthritis Rheum 2005 May;52(5):1595-603.
  42. Discrepancy between the in vitro and in vivo effects of murine mesenchymal stem cells on T-cell proliferation and collagen-induced arthritis. Arthritis Res Ther 2010;12(1):R31.
  43. Role of mesenchymal stem cells in reestablishing immunologic tolerance in auto-immune rheumatic diseases. Arthritis Rheum 2011 Sep;63(9):2547-57.
  44. Transplantation of umbilical cord mesenchymal stem cells alleviates lupus nephritis in MRL/lpr mice. Lupus 2010 Nov; 19(13):1502-14.
  45. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells 2009 Jun;27(6):1421-32.
  46. Transplantation of human bone marrow mesenchymal stem cell ameliorates the autoimmune pathogenesis in MRL/lpr mice. Cell Mol Immunol 2008 Dec;5(6):417-24.
  47. Interferon-gamma-dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus. Arthritis Rheum 2010 Sep;62(9):2776-86.
  48. Allogeneic mesenchymal stem cells do not protect NZBx NZW F1 mice from developing lupus disease. Clin Exp Immunol 2010 Jul 1;161(1):176-86.
  49. Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: A pilot clinical study. Ann Rheum Dis 2010 Aug;69(8):1423-29.
  50. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum 2010 Aug;62(8):2467-75.
  51. Autologous mesenchymal stem cell treatment increased T regulatory cells with no effect on disease activity in two systemic lupus erythematosus patients. Lupus 2010 Mar;19(3):317-22.
  52. Marked improvement of severe progressive systemic sclerosis after transplantation of mesenchymal stem cells from an allogeneic haploidentical-related donor mediated by ligation of CD137L. Leukemia 2008 May;22(5):1062-64.
  53. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005 Sep 1;106(5):1755-61.
  54. Human mesenchymal stem cells abrogate experimental allergic encephalomyelitis after intraperitoneal injection, and with sparse CNS infiltration. Neurosci Lett 2008 Dec 19;448(1):71-73.
  55. Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. J Immunol 2009 May 15;182(10):5994-6002.
  56. Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells 2009 Oct;27(10):2624-35.
  57. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol 2010 Oct;67(10):1187-94.
  58. Does mesenchymal stem cell therapy help multiple sclerosis patients? Report of a pilot study. Iran J Immunol 2007 Mar;4(1):50-57.
  59. Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: A pilot study. J Neuroimmunol (Clinical Trial, Phase I Comparative Study Research Support, Non-US Govt) 2010 Oct 8;227(1-2):185-89.
  60. Stem cell treatment in amyotrophic lateral sclerosis. J Neurol Sci 2008 Feb 15;265(1-2):78–83.
  61. Administration of bone marrow stromal cells ameliorates experimental autoimmune myasthenia gravis by altering the balance of Th1/Th2/Th17/Treg cell subsets through the secretion of TGF-beta. J Neuroimmunol 2009 Feb 15;207(1-2):83–91.
  62. Bone marrow-derived mesenchymal stem cells ameliorate autoimmune enteropathy independently of regulatory T cells. Stem Cells 2008 Jul;26(7):1913-19.
  63. Mesenchymal stem cells: Stem cell therapy perspectives for type 1 diabetes. Diabetes Metab 2009 Apr;35(2):85-93.
  64. Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J Immunol 2006 Jun 15;176(12):7761-67.
  65. Mesenchymal stem cells of cord blood origin are effective at preventing but not treating graft-versus-host disease. Leukemia 2007 Sep;21(9):1992-99.
  66. Co-infusion of donor bone marrow with host mesenchymal stem cells treats GVHD and promotes vascularized skin allograft survival in rats. Clin Immunol 2008 Jun;127(3):348-58.
  67. Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells 2006 Nov;24(11):2582-91.
  68. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. Lancet 2008 May 10;371(9624):1579-86.
  69. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004 May 1;363(9419):1439-41.
  70. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005 May;11(5):389-98.
  71. Administration of donor-derived mesenchymal stem cells can prolong the survival of rat cardiac allograft. Transplant Proc 2006 Nov;38(9):3046-51.
  72. Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance. Am J Transplant 2009 Aug;9(8):1760-72.
  73. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: A randomized controlled trial. JAMA 2012 Mar 21;307(11):1169-77.
  74. Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol 2007 Aug 1;179(3): 1855-63.
  75. Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats. Am J Respir Crit Care Med 2009 Dec 1;180(11):1131-42.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.